Zinaida Boutaeva, M.D. Psychiatry & Neurology - Addiction Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 6232 Avalon Dr W, Orange, CT 06477 Phone: 203-908-3138 |
News Archive
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).
Veterans with substance use disorders who die by suicide are more likely to use violent means (such as a firearm) rather than nonviolent means (such as a drug overdose), new research suggests.
Spero Health, Inc., a newly formed healthcare organization specializing in local, affordable, outpatient care for individuals suffering from substance use disorder, announced that it has acquired investment growth capital to meet the demand in communities across the country for high-quality, comprehensive and integrated addiction treatment services.
Researchers at the University of Minnesota Medical School have discovered the gene responsible for a type of ataxia, an incurable degenerative brain disease affecting movement and coordination.
› Verified 1 days ago